Fruscio Robert, Lissoni Andrea A, Frapolli Roberta, Corso Silvia, Mangioni Costantino, D'Incalci Maurizio, Zucchetti Massimo
Clinica Ostetrica e Ginecologica, San Gerardo Hospital, University of Milan-Bicocca, Monza, MI, Italy.
Cancer Chemother Pharmacol. 2006 Sep;58(3):319-25. doi: 10.1007/s00280-005-0160-y. Epub 2005 Dec 13.
Plasma protein binding is an important factor for many drugs that can influence the tissue distribution and pharmacokinetics. alpha(1)-acid glycoprotein (AGP) is an acute-phase protein that can increase in plasma of patients with several pathological conditions including cancer. Studies performed in cultured cells indicate that paclitaxel cytotoxicity is reduced by adding AGP and the sensitivity to paclitaxel is restored by displacing its binding to AGP with clindamycin, resulting in an increased paclitaxel cell uptake. The purpose of this study was to evaluate whether clindamycin modifies paclitaxel pharmacokinetics also in cancer patients.
Sixteen patients with advanced ovarian cancer, previously treated with surgery and chemotherapy were enrolled in this study. A pharmacokinetic study of paclitaxel was performed in the first three cycles of the consolidation therapy (paclitaxel and carboplatin) in each patient. In these cycles paclitaxel was administered alone and with two different doses (600 and 1,200 mg) of concurrent clindamycin. The sequence of the three treatments was randomly assigned in each patient in order to avoid the same order of treatments.
Paclitaxel pharmacokinetics were partly modified by the concurrent administration of clindamycin. C (max) and AUC(0-last) of paclitaxel were significantly higher when the drug was given alone than when it was coadministered with 1,200 mg clindamycin. Moreover, AGP concentrations seem to have a small but statistically significant influence on paclitaxel pharmacokinetic, since AUC(0-last) showed a positive significant correlation with AGP plasma concentration when paclitaxel was given alone. The linear relation was lost when paclitaxel was coadministered with 1,200 mg clindamycin. Toxicity was not influenced by the coadministration of clindamycin.
The hypothesis that clindamycin could affect paclitaxel pharmacokinetics seems to be verified with this study. Nevertheless, changes induced by giving the combination of the two drugs are minimal and thus of questionable clinical relevance.
血浆蛋白结合是许多药物的一个重要因素,它会影响药物的组织分布和药代动力学。α1-酸性糖蛋白(AGP)是一种急性期蛋白,在包括癌症在内的多种病理状态患者的血浆中会升高。在培养细胞中进行的研究表明,添加AGP会降低紫杉醇的细胞毒性,而用克林霉素取代其与AGP的结合可恢复对紫杉醇的敏感性,从而增加紫杉醇的细胞摄取。本研究的目的是评估克林霉素是否也会改变癌症患者体内紫杉醇的药代动力学。
16例先前接受过手术和化疗的晚期卵巢癌患者纳入本研究。对每位患者在巩固治疗(紫杉醇和卡铂)的前三个周期进行紫杉醇的药代动力学研究。在这些周期中,单独给予紫杉醇,并同时给予两种不同剂量(600和1200mg)的克林霉素。为避免治疗顺序相同,在每位患者中随机分配三种治疗的顺序。
同时给予克林霉素会部分改变紫杉醇的药代动力学。单独给予紫杉醇时,其C(max)和AUC(0-last)显著高于与1200mg克林霉素合用时。此外,AGP浓度似乎对紫杉醇药代动力学有微小但具有统计学意义的影响,因为单独给予紫杉醇时,AUC(0-last)与AGP血浆浓度呈显著正相关。当紫杉醇与1200mg克林霉素合用时,这种线性关系消失。克林霉素的联合使用对毒性没有影响。
本研究似乎验证了克林霉素可能影响紫杉醇药代动力学的假设。然而,两种药物联合使用所引起的变化极小,因此临床相关性存疑。